These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22018938)

  • 1. Efficacy of minocycline and tigecycline in a hamster model of leptospirosis.
    Tully CC; Hinkle MK; McCall S; Griffith ME; Murray CK; Hospenthal DR
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):366-9. PubMed ID: 22018938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of timing and duration of azithromycin therapy of leptospirosis in a hamster model.
    Moon JE; Rivard RG; Griffith ME; Ressner RA; McCall S; Reitstetter RE; Hospenthal DR; Murray CK
    J Antimicrob Chemother; 2007 Jan; 59(1):148-51. PubMed ID: 17110394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model.
    Griffith ME; Moon JE; Johnson EN; Clark KP; Hawley JS; Hospenthal DR; Murray CK
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2615-7. PubMed ID: 17470646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary evaluation of antimicrobial agents for treatment of Leptospira interrogans serovar pomona infection in hamsters and swine.
    Alt DP; Bolin CA
    Am J Vet Res; 1996 Jan; 57(1):59-62. PubMed ID: 8720239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory treatment with thalidomide in experimental leptospirosis in Golden Syrian hamsters (Mesocricetus auratus).
    Soares LM; Macedo JO; de Azevedo EC; Santos CS; Sampaio Mde Q; dos Santos AC; dos Reis MG; Athanazio DA
    Trans R Soc Trop Med Hyg; 2014 Feb; 108(2):105-11. PubMed ID: 24361944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of macrolides and telithromycin against leptospirosis in a hamster model.
    Moon JE; Ellis MW; Griffith ME; Hawley JS; Rivard RG; McCall S; Hospenthal DR; Murray CK
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1989-92. PubMed ID: 16723556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of cefepime, ertapenem and norfloxacin against leptospirosis and for the clearance of pathogens in a hamster model.
    Zhang W; Zhang N; Wang W; Wang F; Gong Y; Jiang H; Zhang Z; Liu X; Song X; Wang T; Ding Z; Cao Y
    Microb Pathog; 2014 Dec; 77():78-83. PubMed ID: 25450882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
    Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials.
    Gardiner D; Dukart G; Cooper A; Babinchak T
    Clin Infect Dis; 2010 Jan; 50(2):229-38. PubMed ID: 20025527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model.
    Feterl M; Govan B; Engler C; Norton R; Ketheesan N
    Int J Antimicrob Agents; 2006 Nov; 28(5):460-4. PubMed ID: 17046208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization.
    Falagas ME; Metaxas EI
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):913-23. PubMed ID: 19803699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice.
    Eckmann C; Heizmann WR; Leitner E; von Eiff C; Bodmann KF
    Chemotherapy; 2011; 57(4):275-84. PubMed ID: 21778715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
    Koomanachai P; Kim A; Nicolau DP
    J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.
    Meagher AK; Ambrose PG; Grasela TH; Ellis-Grosse EJ
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):165-71. PubMed ID: 16105560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.
    Grolman DC
    Int J Infect Dis; 2007 May; 11 Suppl 1():S7-15. PubMed ID: 17603950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imbalanced mortality evidence for tigecycline: 2011, the year of the meta-analysis.
    Verde PE; Curcio D
    Clin Infect Dis; 2012 Aug; 55(3):471-2. PubMed ID: 22511552
    [No Abstract]   [Full Text] [Related]  

  • 18. One-year experience with tigecycline in treating serious infections in severely burned patients.
    Lipový B; Rihová H; Hanslianová M; Brychta P
    Acta Chir Plast; 2009; 51(3-4):69-71. PubMed ID: 20514890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
    Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tigecycline-induced acute pancreatitis: case report and literature review.
    Hung WY; Kogelman L; Volpe G; Iafrati M; Davidson L
    Int J Antimicrob Agents; 2009 Nov; 34(5):486-9. PubMed ID: 19540093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.